By 12 to 24 hours post-injection, some people experience mild nausea, particularly if they eat quickly or consume high-fat foods
Its table puts nausea at 25 to 40 percent of patients and vomiting at 5 to 15 percent, describing vomiting as less frequent and as something that often accompanies moderate-to-severe nausea
Topical and Systemic Treatments Topical corticosteroids are often used first to reduce inflammation and itching, while topical calcineurin inhibitors (TCIs) are a non-steroidal option for sensitive areas
Delayed Gastric Emptying One of cagrilintide's most pronounced effects is slowing the rate of gastric emptying through activation of amylin receptors in the area postrema and vagal afferent pathways [5] : Central Nervous System Signaling: Activation of AMY1 receptors in the area postrema initiates vagal efferent signals that reduce gastric motility and pyloric relaxation [15] Direct Peripheral Effects: AMY3 receptor activation in the stomach and proximal small intestine may contribute to local motor function regulation [16] Metabolic Consequences: Delayed gastric emptying reduces the rate of glucose appearance in the bloodstream, lowering postprandial glucose excursions without increasing insulin demand [5] In Phase 2 trials, cagrilintide demonstrated dose-dependent reductions in gastric emptying rate, with effects sustained over the week-long dosing interval [9]
It belongs to a novel class of agents known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
thetaiotaomicron , the two bacteria candidates selected from our microbiome analysis, can modulate host GLP-1 levels and locomotion
